jeffrey_kasher

DrugDev looks to Lilly for chairman role

pharmafile | June 15, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drugdev, jeffrey kasher, lilly 

Dr Jeffrey Kasher has joined US healthcare tech firm DrugDev as the chairman of its advisory board.

Kasher takes 28 years of experience working at Eli Lilly to the clinical research team that offers tech solutions to help sponsors, CROs and sites to do more trials.

In 2013 CenterWatch named Kasher one of the “20 Innovators Changing the Face of the Clinical Trials Industry”. 

Advertisement

“Jeff Kasher doesn’t work in clinical research innovation, he is clinical research innovation – and we couldn’t be more proud to have the man who essentially defined the term advising us on how to make the maximum impact on the way people run clinical trials,” says Ibraheem Mahmood, president and chief executive of DrugDev.

“The only negative thing I can say about Jeff, especially coming from a company devoted to achieving wellness, is he makes us all look bad by competing in Iron Man competitions and running marathons,” Mahmood adds.

 

Related Content

NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE

BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …

The Gateway to Local Adoption Series

Latest content